Hyderabad-based Suven Life Sciences announced that it has started Phase I clinical trial of its experimental drug for treating Alzheimer's and schizophrenia.
The company revealed that it has submitted the data for Investigational New Drug Application with the US Food and Drug Administration after wrapping up all the pre-clinical, safety and early toxicological studies.
AdvertisementThe approval will provide it with the authorization to conduct the Phase 1 clinical trial of the investigational drug, which the company claims to be a 'potent, selective, brain penetrant and orally active Histamine H3 antagonist' in treating the cognitive effects associated with Alzheimer's and schizophrenia.
"We are very pleased that the second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia with high unmet medical need which has huge market potential globally", The CEO of Suven, Vekat Jasti said.
P Transparent Artificial Blood Vessel Developed to Study How Cancers Spread Sanofi’s Dengue Vaccine Meets Goal in Clinical Trial M
You May Also Like